This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs.
BMYPositive Net Change PFENegative Net Change ALKSNegative Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
After Golden Cross, Enterprise Financial Services (EFSC)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
EFSCNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
NBIX heads into fourth-quarter earnings with Ingrezza sales strength, growing Crenessity revenues and rising focus on late-stage pipeline updates.
MRNANegative Net Change NBIXPositive Net Change CRSPNegative Net Change CSTLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?
by Zacks Equity Research
GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Stock Market News for Feb 5, 2026
by Zacks Equity Research
U.S. stock markets closed mixed on Wednesday as sector rotation by market participants continued.
AMDNegative Net Change ADPNegative Net Change AMGNPositive Net Change
biotechnology business-services semiconductor
Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?
by Ethan Feller
Amgen stock pushes to record highs following a strong earnings report. Is it a buy?
AAPLNegative Net Change MSFTNegative Net Change AMGNPositive Net Change
biotechnology medical pharmaceuticals
Northwest Bancshares (NWBI)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NWBINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Pathward Financial (CASH) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CASHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales
by Zacks Equity Research
NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, reshaping its growth mix.
NVSPositive Net Change RHHBYNegative Net Change BAYRYPositive Net Change RNAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View
by Zacks Equity Research
Novo Nordisk beats Q4 earnings and sales estimates, but shares slide after management forecasts a 5-13% decline in 2026 sales and operating profit.
NVONegative Net Change LLYNegative Net Change ALKSNegative Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals